BioBiz Buzz
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.
Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Disclaimer
https://biobizbuzz.com/disclaimer/
Podcasting since 2025 • 13 episodes
BioBiz Buzz
Latest Episodes
13. Tackling the undruggable: How Beactica's protein degradation platform might transform glioblastoma treatment
Targeted protein degradation (TPD) represents one of the most transformative advances in drug discovery, with the global market projected to expand from USD 641 million in 2025 to as much as USD 9.85 billion by 2035. This rapidly ev...
•
Season 1
•
Episode 13
•
31:51
12. Revolution technology set to transform breast cancer diagnosis and treatment.
Breast cancer affects women of all ages after puberty in every country. In 2022, the disease struck an estimated 2.3 million women and claimed 670 000 lives globally, according to the World Health Organization. The Global Breast Cancer Initiati...
•
Season 1
•
Episode 12
•
19:54
11. A technological breakthrough in the diagnosis of skin cancer
AI-based software solutions are increasingly being used as a second pair of eyes to help clinicians with the early diagnosis of diseases. With skin cancer seeing increasing rates of incidence and mortality, software solutions hold the key to he...
•
Season 1
•
Episode 11
•
26:14
10. How Bioxodes is using tick saliva to create an ICH stroke treatment breakthrough
In a disease where hope has been scarce for decades, Belgian biotech Bioxodes is rewriting the rules of stroke treatment. Join your host Mike Ward in conversation with CEO Marc Dechamps as he reveals how his team transformed an unlikely discove...
•
Season 1
•
Episode 10
•
26:26
9. Beyond Billion-Dollar Bets: How Affibody Might Solve Radioligand Therapy's Greatest Challenges
The radioligand therapy market will be worth $42 billion by 2032. However, beneath the headline-grabbing acquisitions lies a complex web of technical and commercial challenges that threaten to limit patient access to these revolutionary cancer ...
•
Season 1
•
Episode 9
•
26:33
